Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 14, Number 2—February 2008

Research

Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic

M. Ruby Siddiqui*Comments to Author  and W. John Edmunds*
Author affiliations: *Health Protection Agency, London, UK;

Main Article

Figure 5

Incremental cost-effectiveness of the test-treat strategy over the treat-only strategy during a pandemic wave (antiviral [AV] stockpile = 14.6 million courses, test stockpile = number of cumulative influenza-like [ILI] cases, clinical attack rate = 25%). QALY, quality-adjusted life year.

Figure 5. Incremental cost-effectiveness of the test-treat strategy over the treat-only strategy during a pandemic wave (antiviral [AV] stockpile = 14.6 million courses, test stockpile = number of cumulative influenza-like [ILI] cases, clinical attack rate = 25%). QALY, quality-adjusted life year.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO